HeartBeam Closes $10 Million Public Offering to Accelerate Cardiac Tech Commercialization
HeartBeam Inc. raised $10 million in a public offering to fund the commercialization of its FDA-cleared 12-lead synthesized ECG system and other cardiac technologies.
HeartBeam Inc. (NASDAQ: BEAT) announced the closing of its underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses. The transaction, completed on April 16, 2026, was supported by key stakeholders including ClearCardio, company leadership, and institutional investors.
The funds will be used to advance the commercialization of HeartBeam’s FDA-cleared 12-lead synthesized ECG system, further development of its extended-wear patch and heart attack detection technologies, expansion of AI capabilities, and for general corporate purposes. This capital injection is crucial for HeartBeam as it seeks to bring its innovative cardiac monitoring solutions to market.
HeartBeam is a medical technology company focused on transforming cardiac care through its cable-free device that collects ECG signals in 3D from three non-coplanar directions and synthesizes them into a 12-lead ECG. The platform is designed for portable use, enabling physicians to monitor patients outside of medical facilities. The company’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025. HeartBeam holds over 20 issued patents related to its technology.
The successful offering underscores investor confidence in HeartBeam’s potential to disrupt the cardiac monitoring market. The company’s technology aims to provide actionable heart intelligence, allowing for early detection of cardiac issues and reducing the need for in-person visits. With the new funding, HeartBeam plans to scale its manufacturing, expand its sales force, and invest in research and development to enhance its product pipeline.
For more details on the offering, the full press release is available at https://ibn.fm/9iNYY. Information on HeartBeam’s cleared indications for use can be found at https://www.heartbeam.com/indications.